UNASSIGNED: We conducted a retrospective cohort study involving patients diagnosed with Delftia acidovorans infection at a tertiary teaching hospital between January 2014 and December 2022. The data included demographic details, comorbidities, bacterial cultures, antibiotic susceptibility, and treatment outcomes.
UNASSIGNED: There were 26 patients diagnosed with Delftia acidovorans infection who were predominantly older with multiple comorbidities. Approximately 76.9% of Delftia acidovorans infection patients had polymicrobial infections. Twenty-one patients had received antibiotics within three months before they developed the Delftia acidovorans infection, and these antibiotics were primarily third-generation cephalosporins, glycopeptides and fluoroquinolones. Antibiotic susceptibility testing showed resistance to aminoglycosides and susceptibility to imipenem, meropenem, ceftazidime, and piperacillin/tazobactam. Treatment outcome showed a mortality rate of 11.5%, mainly in patients with malignancy and advanced age.
UNASSIGNED: Delftia acidovorans infections predominantly affect older patients with multiple comorbidities. In terms of antibiotic therapy, carbapenems, cephalosporins, and piperacillin/tazobactam with antipseudomonal activity could all be considered.
■我们在2014年1月至2022年12月之间在三级教学医院进行了一项回顾性队列研究,涉及被诊断为Delftiaacidovorans感染的患者。数据包括人口统计细节,合并症,细菌培养物,抗生素敏感性,和治疗结果。
■有26例患者被诊断为Delftiaacidovorans感染,主要是年龄较大,有多种合并症。大约76.9%的Delftiaacidovorans感染患者患有多微生物感染。21名患者在发生Delftiaacidovorans感染之前的三个月内接受了抗生素治疗,这些抗生素主要是第三代头孢菌素,糖肽类和氟喹诺酮类。抗生素药敏试验显示对氨基糖苷类的耐药性和对亚胺培南的敏感性,美罗培南,头孢他啶,还有哌拉西林/他唑巴坦.治疗结果显示死亡率为11.5%,主要见于恶性肿瘤和高龄患者。
■Delftiaacidovorans感染主要影响患有多种合并症的老年患者。在抗生素治疗方面,碳青霉烯类,头孢菌素,和哌拉西林/他唑巴坦具有抗假单胞菌活性都可以考虑。